CytRx (CYTR) Tops Q1 EPS by 52c

CytRx (NASDAQ: CYTR) reported Q1 EPS of $0.31, $0.52 better than the analyst estimate of ($0.21).

CytRx recently appointed two new independent members to its Board of Directors. Effective April 30, 2015, Eric J. Selter, J.D. joined the Board and will serve as Chairman of the audit committee and as a member of the compensation committee. Mr. Selter currently serves as an owner, Chief Operating Officer and Vice President at Morton Capital Management and brings over 33 years of finance and strategic business experience to the CytRx Board. In March, the Company appointed Anita J. Chawla, PhD, to its Board of Directors, adding significant operational and commercial expertise. Dr. Chawla brings over 25 years of experience as an economist in the health care industry to CytRx, with a proven track record helping pharmaceutical, biotechnology, medical device, and diagnostic companies achieve their product development and commercialization objectives.

For earnings history and earnings-related data on CytRx (CYTR) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance